Share on StockTwits

Dechra Pharmaceuticals plc (LON:DPH)‘s stock had its “hold” rating reaffirmed by research analysts at Oriel Securities Ltd in a report released on Tuesday. They currently have a GBX 690 ($11.84) target price on the stock. Oriel Securities Ltd’s target price would suggest a potential downside of 5.87% from the company’s current price.

Dechra Pharmaceuticals plc (LON:DPH) opened at 726.00 on Tuesday. Dechra Pharmaceuticals plc has a one year low of GBX 655.00 and a one year high of GBX 755.00. The stock has a 50-day moving average of GBX 708. and a 200-day moving average of GBX 696.7. The company’s market cap is £633.1 million.

DPH has been the subject of a number of other recent research reports. Analysts at N+1 Singer reiterated a “buy” rating on shares of Dechra Pharmaceuticals plc in a research note on Tuesday. They now have a GBX 760 ($13.04) price target on the stock. Separately, analysts at FinnCap reiterated a “buy” rating on shares of Dechra Pharmaceuticals plc in a research note on Tuesday. They now have a GBX 800 ($13.72) price target on the stock. Finally, analysts at FinnCap reiterated a “buy” rating on shares of Dechra Pharmaceuticals plc in a research note on Wednesday, June 18th. They now have a GBX 800 ($13.72) price target on the stock. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of GBX 781 ($13.40).

Dechra Pharmaceuticals PLC is a United Kingdom-based veterinary pharmaceutical company. The Company is engaged in developing, manufacturing, distributing, selling and marketing of animal products to the veterinary industry.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.